<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">sredob</journal-id><journal-title-group><journal-title xml:lang="ru">Здоровье населения и среда обитания – ЗНиСО</journal-title><trans-title-group xml:lang="en"><trans-title>Public Health and Life Environment – PH&amp;LE</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-5238</issn><issn pub-type="epub">2619-0788</issn><publisher><publisher-name>ФБУЗ ФЦГиЭ Роспотребнадзора</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35627/2219-5238/2023-31-1-13-19</article-id><article-id custom-type="elpub" pub-id-type="custom">sredob-1280</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СОЦИОЛОГИЯ МЕДИЦИНЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MEDICAL SOCIOLOGY</subject></subj-group></article-categories><title-group><article-title>От мониторинга приверженности прививкам медицинских работников в условиях пандемии COVID-19 к преодолению коммуникативных рисков в процессе вакцинопрофилактики</article-title><trans-title-group xml:lang="en"><trans-title>From Monitoring the Commitment to Inoculations among Healthcare Workers during the COVID-19 Pandemic to Overcoming Communication Risks in the Process of Vaccination</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5441-184X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Платонова</surname><given-names>T. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Platonova</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Платонова Татьяна Александровна – к.м.н., заведующая эпидемиологическим отделом, врач-эпидемиолог</p><p>ул. Шейнкмана, стр. 113, г. Екатеринбург, 620144</p></bio><bio xml:lang="en"><p>Tatyana A. Platonova, Cand. Sci. (Med), Head of the Department of Epidemiology, epidemiologist, European Medical Center “UMMC–Health”;</p><p>Scheinkman Street, Yekaterinburg, 620144</p></bio><email xlink:type="simple">fill.1990@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4812-2165</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голубкова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Golubkova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голубкова Алла Александровна – д.м.н., профессор, ведущий научный сотрудник лаборатории инфекций, связанных с оказанием медицинской помощи; профессор кафедры эпидемиологии</p><p>ул. Новогиреевская, д. 3а, г. Москва, 111123 ул. Баррикадная, д. 2/1, стр. 1, г. Москва, 125993</p></bio><bio xml:lang="en"><p>Alla A. Golubkova, Dr. Sci. (Med.), Prof., Leading Researcher, Laboratory of Healthcare-Associated Infections, Central Research Institute of Epidemiology; Professor, Department of Epidemiology, Russian Medical Academy of Continuous Professional Education</p><p>3А Novogireevskaya Street, Moscow, 111123</p><p>Bldg 1, 2/1 Barrikadnaya Street, Moscow, 125993</p></bio><email xlink:type="simple">allagolubkova@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1692-522X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скляр</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sklyar</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Скляр Михаил Семенович – д.м.н., генеральный директор; советник генерального директора</p><p>ул. Шейнкмана, стр. 113, г. Екатеринбург, 620144</p><p>пр. Успенский, д. 1, г. Верхняя Пышма, 624091</p></bio><bio xml:lang="en"><p>Mikhail S. Sklyar, Dr. Sci. (Med.), Director General, European Medical Center “UMMC–Health”, Advisor to the UMMC Director General</p><p>113 Scheinkman Street, Yekaterinburg, 620144</p><p>1 Uspensky Avenue, Verkhnyaya Pyshma, 624091</p></bio><email xlink:type="simple">info@ugmk-clinic.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5003-1110</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сисин</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Sisin</surname><given-names>Е I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сисин Евгений Игоревич – к.м.н., доцент кафедры инфекционных болезней с курсом эпидемиологии; врач-эпидемиолог отдела обеспечения эпидемиологического надзора</p><p>ул. Мира, д. 40, г. Ханты-Мансийск, 628011</p><p>ул. Рознина, д. 72, г. Ханты-Мансийск, 628011</p></bio><bio xml:lang="en"><p>Еvgeniy I. Sisin, Cand. Sci. (Med.), Assoc. Prof., Department of Infectious Diseases with the Course of Epidemiology, Khanty-Mansiysk State Medical Academy; epidemiologist, Department of Epidemiological Surveillance, Center for Hygiene and Epidemiology in the Khanty-Mansi Autonomous Okrug</p><p>40 Mira Street, Khanty-Mansiysk, 628011</p><p>72 Roznin Street, Khanty-Mansiysk, 628011</p></bio><email xlink:type="simple">evg-sisin1@yandex.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9749-4611</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смирнова Светлана Сергеевна – к.м.н., руководитель Урало-Сибирского научно-методического центра по профилактике инфекций, связанных с оказанием медицинской помощи; доцент кафедры эпидемиологии, социальной гигиены и организации госсанэпидслужбы</p><p>ул. Летняя, д. 23, г. Екатеринбург, 620030</p><p>ул. Репина, д. 3, г. Екатеринбург, 620028</p></bio><bio xml:lang="en"><p>Svetlana S. Smirnova, Cand. Sci. (Med.), Head, Ural-Siberian Scientific and Methodological Center for Prevention of Healthcare-Associated Infections, Yekaterinburg Research Institute of Viral Infections, State Research Center for Virology and Biotechnology “Vector”; Assoc. Prof., Department of Epidemiology, Social Hygiene and Organization of State Sanitary and Epidemiological Service, Ural State Medical University</p><p>23 Letnyaya Street, Yekaterinburg, 620030</p><p>3 Repin Street, Yekaterinburg, 620028</p></bio><email xlink:type="simple">smirnova_ss69@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0652-1996</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Томенко</surname><given-names>Т. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Tomenko</surname><given-names>T. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Томенко Татьяна Рафаиловна – к.м.н., заведующая центром мозговых дисфункций и эпилепсии; ассистент кафедры неврологии, нейрохирургии и медицинской генетики; заведующий лабораторией когнитивно-поведенческих исследований человека</p><p>ул. Шейнкмана, стр. 113, г. Екатеринбург, 620144</p><p>ул. Репина, д. 3, г. Екатеринбург, 620028</p><p>ул. Мира, д. 19, г. Екатеринбург, 620002</p></bio><bio xml:lang="en"><p>Tatiana R. Tomenko, Cand. Sci. (Med.), Head, Center for Brain Dysfunction and Epilepsy, European Medical Center “UMMC–Health”; Assistant, Department of Neurology, Neurosurgery and Medical Genetics, Ural State Medical University; Head, Human Cognition and Behavior Research Laboratory, Ural Federal University named after the First President of Russia B.N. Yeltsin</p><p>113 Scheinkman Street, Yekaterinburg, 620144</p><p>3 Repin Street, Yekaterinburg, 620028</p><p>19 Mira Street, Yekaterinburg, 620002</p></bio><email xlink:type="simple">TomenkoTR@ugmk-clinic.ru</email><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9542-6917</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рожков</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Rozhkov</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рожков Михаил Сергеевич – лаборант-исследователь лаборатории когнитивно-поведенческих исследований человека</p><p>ул. Мира, д. 19, г. Екатеринбург, 620002</p></bio><bio xml:lang="en"><p>Mikhail S. Rozhkov, Researcher, Human Cognition and Behavior Research Laboratory, Ural Federal University named after the First President of Russia B.N. Yeltsin</p><p>19 Mira Street, Yekaterinburg, 620002</p></bio><email xlink:type="simple">vashevsio@mail.ru</email><xref ref-type="aff" rid="aff-7"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ООО «Европейский медицинский центр “УГМК-Здоровье”»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>European Medical Center “UMMC–Health”</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФБУН «Центральный научно-исследовательский институт эпидемиологии» Роспотребнадзора; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Research Institute of Epidemiology; Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ООО «Европейский медицинский центр “УГМК-Здоровье”»; ОАО «УГМК»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>European Medical Center “UMMC–Health”; Ural Mining and Metallurgical Company (UMMC)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>БУВО ХМАО – Югры «Ханты-Мансийская государственная медицинская академия»; ФБУЗ «Центр гигиены и эпидемиологии в Ханты-Мансийском автономном округе – Югре»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Khanty-Mansiysk State Medical Academy; Center for Hygiene and Epidemiology in the Khanty-Mansi Autonomous Okrug – Yugra</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Екатеринбургский НИИ вирусных инфекций ФБУН ГНЦ вирусологии и биотехнологии «Вектор» Роспотребнадзора; ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yekaterinburg Research Institute of Viral Infections, State Research Center for Virology and Biotechnology “Vector”; Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ООО «Европейский медицинский центр “УГМК-Здоровье”»; ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России; ФГАОУ ВО «Уральский федеральный университет имени первого Президента России Б.Н. Ельцина»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>European Medical Center “UMMC–Health”; Ural State Medical University; Ural Federal University named after the First President of Russia B.N. Yeltsin</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ФГАОУ ВО «Уральский федеральный университет имени первого Президента России Б.Н. Ельцина»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural Federal University named after the First President of Russia B.N. Yeltsin</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>02</month><year>2023</year></pub-date><volume>31</volume><issue>1</issue><fpage>13</fpage><lpage>19</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Платонова T.A., Голубкова А.А., Скляр М.С., Сисин Е.И., Смирнова С.С., Томенко Т.Р., Рожков М.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Платонова T.A., Голубкова А.А., Скляр М.С., Сисин Е.И., Смирнова С.С., Томенко Т.Р., Рожков М.С.</copyright-holder><copyright-holder xml:lang="en">Platonova T.A., Golubkova A.A., Sklyar M.S., Sisin Е.I., Smirnova S.S., Tomenko T.R., Rozhkov M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://zniso.fcgie.ru/jour/article/view/1280">https://zniso.fcgie.ru/jour/article/view/1280</self-uri><abstract><p>Введение. Управление эпидемическим процессом новой коронавирусной инфекции (COVID-19) возможно только вакцинопрофилактикой. Однако, несмотря на наличие и доступность для профилактики этого заболевания целого ряда эффективных иммунобиологических препаратов, организаторам здравоохранения зачастую приходится сталкиваться с негативным отношением населения к вакцинации, в том числе и в среде медицинских работников.Цель исследования – с использованием современных онлайн-ресурсов оценить приверженность прививкам против COVID-19 сотрудников медицинских организаций в разные периоды пандемии и обосновать необходимость разработки эффективных практик преодоления коммуникативных рисков в процессе вакцинопрофилактики.Материалы и методы. Исследование проведено в несколько последовательных этапов, соответствующих пяти эпидемическим подъемам («волнам») заболеваемости COVID-19 в Российской Федерации, посредством онлайн-опросов медицинских работников на Google-платформе. Общее количество респондентов составило 5304. В работе использованы социологический и статистический методы исследования.Результаты. Установлено, что отношение к вакцинации против COVID-19 сотрудников медицинских организаций было неоднозначным и динамически менялось с течением времени, с постепенным повышением приверженности прививкам. Потенциальной группой риска с негативной позицией в отношении вакцинации были средний медицинский персонал и сотрудники немедицинских специальностей, женского пола, со стажем работы до 5 лет. Недостаточный уровень приверженности вакцинопрофилактике COVID-19 среди сотрудников медицинских организаций отмечен и в других странах, что является серьезной проблемой мирового масштаба, так как препятствует победе над новым заболеванием.Заключение. В данном исследовании с использованием современных онлайн-ресурсов проведена оценка приверженности прививкам медицинских работников. Показан недостаточный уровень приверженности вакцинопрофилактике персонала, что требует оперативного проведения образовательных мероприятий для повышения их теоретической подготовки и обучения современным практикам эффективных коммуникаций.</p></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction: The epidemic process of the novel coronavirus disease (COVID-19) can be managed only through vaccination. Yet, despite the availability of effective immunobiological preparations, health administrators often face a negative attitude of the population, including healthcare professionals, to vaccination.</p></sec><sec><title>Objective</title><p>Objective: To establish commitment of workers of health facilities to vaccination against COVID–19 during different periods of the pandemic using modern online resources and to justify the need to develop effective practices of dealing with communicative risks in the course of vaccination.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: The study was conducted in several successive stages corresponding to five waves of the COVID-19 pandemic in the Russian Federation by means of an online survey of 5,304 health workers using Google Forms. We applied sociological and statistical methods of research.</p></sec><sec><title>Results</title><p>Results: We observed that the attitude to vaccination against COVID-19 among the employees of health institutions was ambiguous and changed over time demonstrating a gradual increase in adherence to inoculations. The potential risk group with a negative attitude towards vaccination included female nurses and workers of non-medical specialties with less than five years of work experience. An insufficient level of commitment to coronavirus vaccination among the personnel of health facilities has been also noted in other countries, which is a serious problem on a global scale hindering the victory over this novel infection.</p></sec><sec><title>Conclusion</title><p>Conclusion: We assessed commitment to inoculations against COVID-19 among medical workers using modern online resources and found its inadequate level necessitating effective interventions aimed at awareness raising and training in modern practices of effective communications.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>вакцинация</kwd><kwd>COVID-19</kwd><kwd>мониторинг приверженности</kwd><kwd>сотрудники медицинских организаций</kwd><kwd>коммуникативные риски</kwd><kwd>пути преодоления</kwd></kwd-group><kwd-group xml:lang="en"><kwd>vaccination</kwd><kwd>COVID-19</kwd><kwd>monitoring of commitment</kwd><kwd>health professionals</kwd><kwd>communication risks</kwd><kwd>solution options</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Брико Н.И., Каграманян И.Н., Никифоров В.В., Суранова Т.Г., Чернявская О.П., Полежаева Н.А. Пандемия COVID-19. Меры борьбы с ее распространением в Российской Федерации // Эпидемиология и вакцинопрофилактика. 2020. Т. 19. № 2. С. 4–12. doi: 10.31631/2073-3046-2020-l9-2-4-12</mixed-citation><mixed-citation xml:lang="en">Briko NI, Kagramanyan IN, Nikiforov VV, Suranova TG, Chernyavskaya OР, Polezhaeva NA. Pandemic COVID-19. Prevention measures in the Russian Federation. Epidemiologiya i Vaktsinoprofilaktika. 2020;19(2):4-12. (In Russ.) doi: 10.31631/2073-3046-2020-19-2-4-12</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: Virology, biology and novel laboratory diagnosis. J Gene Med. 2021;23(2):e3303. doi: 10.1002/jgm.3303</mixed-citation><mixed-citation xml:lang="en">Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: Virology, biology and novel laboratory diagnosis. J Gene Med. 2021;23(2):e3303. doi: 10.1002/jgm.3303</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography (Lond). 2021;27(2):682687. doi: 10.1016/j.radi.2020.09.010</mixed-citation><mixed-citation xml:lang="en">Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography (Lond). 2021;27(2):682687. doi: 10.1016/j.radi.2020.09.010</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Samudrala PK, Kumar P, Choudhary K, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883:173375. doi: 10.1016/j.ejphar.2020.173375</mixed-citation><mixed-citation xml:lang="en">Samudrala PK, Kumar P, Choudhary K, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883:173375. doi: 10.1016/j.ejphar.2020.173375</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85-100. doi: 10.1016/j.biochi.2020.09.018.</mixed-citation><mixed-citation xml:lang="en">Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85-100. doi: 10.1016/j.biochi.2020.09.018.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hossain MM, Tasnim S, Sultana A, et al. Epidemiology of mental health problems in COVID-19: a review. F1000Res. 2020;9:636. doi: 10.12688/f1000research.24457.1.</mixed-citation><mixed-citation xml:lang="en">Hossain MM, Tasnim S, Sultana A, et al. Epidemiology of mental health problems in COVID-19: a review. F1000Res. 2020;9:636. doi: 10.12688/f1000research.24457.1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Onyeaka H, Anumudu CK, Al-Sharify ZT, Egele-Godswill E, Mbaegbu P. COVID-19 pandemic: A review of the global lockdown and its far-reaching effects. Sci Prog. 2021;104(2):368504211019854. doi: 10.1177/00368504211019854.</mixed-citation><mixed-citation xml:lang="en">Onyeaka H, Anumudu CK, Al-Sharify ZT, Egele-Godswill E, Mbaegbu P. COVID-19 pandemic: A review of the global lockdown and its far-reaching effects. Sci Prog. 2021;104(2):368504211019854. doi: 10.1177/00368504211019854.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS One. 2021;16(7):e0254523. doi: 10.1371/journal.pone.0254523.</mixed-citation><mixed-citation xml:lang="en">Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS One. 2021;16(7):e0254523. doi: 10.1371/journal.pone.0254523.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mamun MA, Sakib N, Gozal D, et al. The COVID-19 pandemic and serious psychological consequences in Bangladesh: A population-based nationwide study. J Affect Disord. 2021;279:462-472. doi: 10.1016/j.jad.2020.10.036.</mixed-citation><mixed-citation xml:lang="en">Mamun MA, Sakib N, Gozal D, et al. The COVID-19 pandemic and serious psychological consequences in Bangladesh: A population-based nationwide study. J Affect Disord. 2021;279:462-472. doi: 10.1016/j.jad.2020.10.036.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Papadopoulou A, Efstathiou V, Yotsidi V, et al. Suicidal ideation during COVID-19 lockdown in Greece: Prevalence in the community, risk and protective factors. Psychiatry Res. 2021;297:113713. doi: 10.1016/j.psychres.2021.113713.</mixed-citation><mixed-citation xml:lang="en">Papadopoulou A, Efstathiou V, Yotsidi V, et al. Suicidal ideation during COVID-19 lockdown in Greece: Prevalence in the community, risk and protective factors. Psychiatry Res. 2021;297:113713. doi: 10.1016/j.psychres.2021.113713.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chen PJ, Pusica Y, Sohaei D, Prassas I, Diamandis EP. An overview of mental health during the COVID-19 pandemic. Diagnosis (Berl). 2021;8(4):403-412. doi: 10.1515/dx-2021-0046.</mixed-citation><mixed-citation xml:lang="en">Chen PJ, Pusica Y, Sohaei D, Prassas I, Diamandis EP. An overview of mental health during the COVID-19 pandemic. Diagnosis (Berl). 2021;8(4):403-412. doi: 10.1515/dx-2021-0046.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Capra ME, Stanyevic B, Giudice A, et al. The Effects of COVID-19 Pandemic and Lockdown on Pediatric Nutritional and Metabolic Diseases: A Narrative Review. Nutrients. 2022;15(1):88. doi: 10.3390/nu15010088.</mixed-citation><mixed-citation xml:lang="en">Capra ME, Stanyevic B, Giudice A, et al. The Effects of COVID-19 Pandemic and Lockdown on Pediatric Nutritional and Metabolic Diseases: A Narrative Review. Nutrients. 2022;15(1):88. doi: 10.3390/nu15010088.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Харченко Е.П. Вакцины против Covid-19: сравнительная оценка рисков аденовирусных векторов // Эпидемиология и Вакцинопрофилактика. 2020. Т. 19. № 5. С. 4–17. doi: 10.31631/20733046-2020-19-5-4-17</mixed-citation><mixed-citation xml:lang="en">Kharchenko EP. Vaccines against Covid-19: The comparative estimates of risks in adenovirus vectors. Epidemiologiya i Vaktsinoprofilaktika. 2020;19(5):4-17. (In Russ.) doi: 10.31631/20733046-2020-19-5-4-17</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Харченко Е.П. Вакцины против COVID-19: сравнения, ограничения, спад пандемии и перспектива ОРВИ // Эпидемиология и Вакцинопрофилактика. 2021. Т.20. №1. С. 4–19. doi: 10.31631/20733046-2021-20-1-4-19</mixed-citation><mixed-citation xml:lang="en">Kharchenko EP. Vaccines against Covid-19: Comparison, limitations, the decrease of pandemic and the perspective of viral respiratory. Epidemiologiya i Vaktsinoprofilaktika 2021;20(1):4-19. (In Russ.) doi: 10.31631/2073-3046-2021-20-1-4-19</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3</mixed-citation><mixed-citation xml:lang="en">Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8</mixed-citation><mixed-citation xml:lang="en">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.</mixed-citation><mixed-citation xml:lang="en">Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mehrotra DV, Janes HE, Fleming TR, et al. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Ann Intern Med. 2021;174(2):221-228. doi: 10.7326/M20-6169.</mixed-citation><mixed-citation xml:lang="en">Mehrotra DV, Janes HE, Fleming TR, et al. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Ann Intern Med. 2021;174(2):221-228. doi: 10.7326/M20-6169.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626-636. doi: 10.1038/s41577-021-00592-1.</mixed-citation><mixed-citation xml:lang="en">Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626-636. doi: 10.1038/s41577-021-00592-1.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26-e35. doi: 10.1016/ S1473-3099(20)30773-8.</mixed-citation><mixed-citation xml:lang="en">Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21(2):e26-e35. doi: 10.1016/ S1473-3099(20)30773-8.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines. 2021;20(1):23-44. doi: 10.1080/14760584.2021.1875824.</mixed-citation><mixed-citation xml:lang="en">Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines. 2021;20(1):23-44. doi: 10.1080/14760584.2021.1875824.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fang E, Liu X, Li M, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94. doi: 10.1038/s41392-022-00950-y.</mixed-citation><mixed-citation xml:lang="en">Fang E, Liu X, Li M, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94. doi: 10.1038/s41392-022-00950-y.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022;387(14):12791291. doi: 10.1056/NEJMoa2208343.</mixed-citation><mixed-citation xml:lang="en">Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022;387(14):12791291. doi: 10.1056/NEJMoa2208343.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0.</mixed-citation><mixed-citation xml:lang="en">Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2022;98(1159):389-394. doi: 10.1136/postgradmedj-2021-140654.</mixed-citation><mixed-citation xml:lang="en">Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2022;98(1159):389-394. doi: 10.1136/postgradmedj-2021-140654.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022;386(21):2011-2023. doi: 10.1056/NEJMoa2203315.</mixed-citation><mixed-citation xml:lang="en">Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022;386(21):2011-2023. doi: 10.1056/NEJMoa2203315.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;12(12):CD015477. doi: 10.1002/14651858.CD015477.</mixed-citation><mixed-citation xml:lang="en">Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;12(12):CD015477. doi: 10.1002/14651858.CD015477.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Dai L, Gao L, Tao L, et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N Engl J Med. 2022;386(22):2097-2111. doi: 10.1056/NEJMoa2202261.</mixed-citation><mixed-citation xml:lang="en">Dai L, Gao L, Tao L, et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N Engl J Med. 2022;386(22):2097-2111. doi: 10.1056/NEJMoa2202261.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Prakash S. Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. Diabetes Metab Syndr. 2022;16(4):102482. doi: 10.1016/j.dsx.2022.102482.</mixed-citation><mixed-citation xml:lang="en">Prakash S. Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. Diabetes Metab Syndr. 2022;16(4):102482. doi: 10.1016/j.dsx.2022.102482.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ермоленко К.Д., Харит С.М., Рулева А.А., Дроздова Л.Ю. Построение диалога с пациентом о вакцинации (научный обзор) // Эпидемиология и Вакцинопрофилактика. 2021. Т. 20. № 1. С. 114–124. doi: 10.31631/2073-3046-2021-20-1-114-124</mixed-citation><mixed-citation xml:lang="en">Ermolenko KD, Kharit SM, Ruleva AA, Drozdova LYu. Establishing a dialogue with a patient on vaccination (scientific review).  Epidemiologiya i Vaktsinoprofilaktika. 2021;20(1):114-124. (In Russ.) doi: 10.31631/2073-3046-2021-20-1-114-124</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Голубкова А.А., Платонова Т.А., Семененко Т.А., Смирнова С.С., Никитская А.Д., Чикунова М.В. Многоуровневый мониторинг приверженности прививкам различных групп населения в условиях пандемии COVID-19: проблемные вопросы // Эпидемиология и Вакцинопрофилактика. 2021. Т. 20. № 6. С. 28–36. doi: 10.31631/2073-3046-2021-20-6-28-36</mixed-citation><mixed-citation xml:lang="en">Golubkova AA, Platonova TA, Semenenko TA, Smirnova SS, Nikitskaya AD, Chikunova MV. Multi-level monitoring of vaccination adherence of various population groups in the context of the COVID-19 pandemic: Problematic issues. Epidemiologiya i Vaktsinoprofilaktika. 2021;20(6):2836. (In Russ.) doi: 10.31631/2073-3046-2021-20-6-28-36</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Галина Н.П. Отношение к иммунопрофилактике врачей различных специальностей // Эпидемиология и Вакцинопрофилактика. 2018. Т. 17. № 3. С. 74–79. doi: 10.31631/2073-3046-2018-17-3-74-79</mixed-citation><mixed-citation xml:lang="en">Galina NP. Analysis of the attitude towards immunization of doctors of various specialties. Epidemiologiya i Vaktsinoprofilaktika. 2018;17(3):74-79. (In Russ.) doi: 10.31631/2073-3046-2018-17-3-74-79</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Hajure M, Tariku M, Bekele F, et al. Attitude towards COVID-19 vaccination among healthcare workers: A systematic review. Infect Drug Resist. 2021;14:3883-3897. doi: 10.2147/IDR.S332792</mixed-citation><mixed-citation xml:lang="en">Hajure M, Tariku M, Bekele F, et al. Attitude towards COVID-19 vaccination among healthcare workers: A systematic review. Infect Drug Resist. 2021;14:3883-3897. doi: 10.2147/IDR.S332792</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Luo C, Yang Y, Liu Y, et al. Intention to COVID-19 vaccination and associated factors among health care workers: A systematic review and meta-analysis of cross-sectional studies. Am J Infect Control. 2021;49(10):1295-1304. doi: 10.1016/j.ajic.2021.06.020</mixed-citation><mixed-citation xml:lang="en">Luo C, Yang Y, Liu Y, et al. Intention to COVID-19 vaccination and associated factors among health care workers: A systematic review and meta-analysis of cross-sectional studies. Am J Infect Control. 2021;49(10):1295-1304. doi: 10.1016/j.ajic.2021.06.020</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Li M, Luo Y, Watson R, et al. Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: A rapid systematic review. Postgrad Med J. 2021;postgradmedj-2021-140195. doi: 10.1136/postgradmedj-2021-140195</mixed-citation><mixed-citation xml:lang="en">Li M, Luo Y, Watson R, et al. Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: A rapid systematic review. Postgrad Med J. 2021;postgradmedj-2021-140195. doi: 10.1136/postgradmedj-2021-140195</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
